

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Monongalia General Hospital 2. 1200 J.D. Anderson Drive Morgantown, WV 26505-3486	In accordance with letter dated March 22, 2018.	4. Expiration Date: October 31, 2021
	3. License number: 47-16259-01 is amended in its entirety to read as follows:	5. Docket No.: 030-10683 Reference No.:

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Iodine-131 permitted by 10 CFR 35.300	C. Any	C. 1.5 curies total	C. For any iodine-131 use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-16259-01

Docket or Reference Number
030-10683

Amendment No. 44

- | | | | |
|---|--|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p> <p>E. Palladium-103 permitted by 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc. , Model STM 1251; Best Medical International, Inc. (formerly Best Industries, Inc.) , Model 2301-2308, or 2309-2316; IsoAid, LLC, Model IAI-125A; North American Scientific, Inc., Model MED3631)</p> <p>E. Sealed Sources (Best Medical International, Inc. (formerly Best Industries, Inc.), Model 2331-2335; North American Scientific, Inc., Model MED3633; Theragenics Corporation, Model TheraSeed 200)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>D. 600 millicuries total</p> <p>E. 600 millicuries total</p> | <p>9. Authorized use</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> <p>E. For any manual brachytherapy procedure permitted by 10 CFR 35.400 for which the patient can be released under the provisions of 10 CFR 35.75.</p> |
|---|--|---|--|

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 1200 J.D. Anderson Drive, Morgantown, West Virginia.
 B. Licensed material listed in Subitem No. 6.B. may be used or stored at the licensee's facilities located at 501 Railroad Avenue, Elkins, West Virginia.
11. The Radiation Safety Officer (RSO) for this license is Mark T. Perna, M.S.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
47-16259-01

Docket or Reference Number
030-10683

Amendment No. 44

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Material and Use

Paul A. Alappat, M.D.	10 CFR 35.100, 10 CFR 35.200
C. David Burtner, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
Frederick J. Gabriele, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
William L. Hirsch, Jr., M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
Evan G. Kupec, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
Jon S. LaPlante, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
John Anthony Leon, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
Joseph R. Migaiolo, M.D.	10 CFR 35.100, 10 CFR 35.200
David C. Rosiello, M.D.	10 CFR 35.100, 10 CFR 35.200
James A. Ross, M.D.	10 CFR 35.100, 10 CFR 35.200
Richard L. Smith, II, M.D.	10 CFR 35.100, 10 CFR 35.200
Michael A. Stewart, M.D.	10 CFR 35.400
Garrett W. Stover, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
W. Parke Thrush, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131
Wesley D. Tuel, M.D.	10 CFR 35.100, 10 CFR 35.200; oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
47-16259-01

Amendment No. 44

Docket or Reference Number
030-10683

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated May 16, 2011 [ML111390327]
 - B. Facsimile received October 10, 2011 [ML112840139]
 - C. Facsimile received December 18, 2012 [ML12354A154]
 - D. Letter received December 28, 2012 [ML13008A498]
 - E. Letter received August 30, 2016 [ML16250A409]
 - F. Letter dated September 21, 2016 [ML16267A160]
 - G. Letter dated September 13, 2017 [ML17262B068]
 - H. Letter dated March 22, 2018 [ML18088A805]
 - I. Letter received April 30, 2018 [ML18124A194]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: May 10, 2018By: Penny Lanzisera
Region 1